Characterizing the tumor RBP-ncRNA circuits by integrating transcriptomics, interactomics and clinical data

Area of Science:

• Molecular Biology
• Genetics
• Oncology

Background:

• Non-coding RNA (ncRNA) and RNA binding protein (RBP) interactions are fundamental to gene regulation and cancer progression.
• Understanding the dynamic regulatory network of ncRNA-RBP interactions, particularly in cancer, remains limited.

Purpose of the Study:

• To systematically dissect dysregulated RNA binding protein-non-coding RNA circuits (RNCs) across various cancer types.
• To investigate the potential of RNCs as prognostic biomarkers and therapeutic targets in cancer.

Main Methods:

• Utilized transcriptomics and interactomics data to identify and analyze aberrant RNCs in 14 tumor types.
• Performed pan-cancer analysis to identify common dysregulated RNCs across multiple cancers.
• Conducted experimental validation to elucidate the role of a specific RNC in cancer progression.

Main Results:

• Identified robust, dysregulated RNCs enriched with cancer-associated genes and drug targets.
• Demonstrated that altered RNCs, but not individual nodes, can jointly predict clinical outcomes, serving as prognostic biomarkers.
• Discovered 30 pan-cancer RNCs and elucidated the role of the hsa-miR-224-5p_MAGI2-AS3_MBNL2 circuit in epithelial-mesenchymal transition (EMT).

Conclusions:

• Dysregulated RNCs are significant in cancer, offering potential as prognostic biomarkers and for drug repurposing.
• Pan-cancer RNC analysis provides novel insights into cancer mechanisms and therapeutic strategies.
• The study highlights the utility of RNCs in understanding ncRNA function, clinical outcomes, and drug discovery in oncology.